Tumor heterogeneity and drug resistance of targeted antitumor agents

The popular application of targeted antitumor agents has greatly improved the efficacies of tumor therapy. However, some patients develop drug resistance after the administration with them for six to twelve months, leading to the failure of treatment. The cause of it is mainly due to tumor heterogen...

Full description

Saved in:
Bibliographic Details
Published inYao hsüeh hsüeh pao Vol. 51; no. 2; p. 197
Main Author He, Qi-yang
Format Journal Article
LanguageChinese
Published China 01.02.2016
Subjects
Antineoplastic Agents - pharmacology
Drug Resistance, Neoplasm
Genomic Instability
Humans
Neoplasms - drug therapy
Neoplastic Stem Cells
Online AccessGet more information

Cover

More Information
Summary:The popular application of targeted antitumor agents has greatly improved the efficacies of tumor therapy. However, some patients develop drug resistance after the administration with them for six to twelve months, leading to the failure of treatment. The cause of it is mainly due to tumor heterogeneity. The genesis of tumor heterogeneity is closely associated with tumor stem cells, genetic instability, cell competition and stochastic events. There are a lot of mechanisms involved in the drug resistance to the targeted agents. Tumor heterogeneity and drug resistance are great challenges for precision oncology and are taken account for the process of research and development of new antitumor agents.
ISSN:0513-4870